Design and development of supersaturated lipid-based drug delivery systems for applications in pharmaceutical industry

dc.availability.bitstreamcontrolled
dc.check.date2024-09-30
dc.contributor.advisorGriffin, Brendan T.en
dc.contributor.advisorexternalHolm, Renéen
dc.contributor.authorIlie, Alexandra-Roxana
dc.contributor.funderHorizon 2020en
dc.date.accessioned2021-09-28T15:55:26Z
dc.date.available2021-09-28T15:55:26Z
dc.date.issued2020-07-04
dc.date.submitted2020-07-04
dc.description.abstractPurpose: The need to administer high doses of poorly water-soluble drugs in preclinical studies has guided pharmaceutical research towards evaluation of supersaturated lipid-based drug delivery systems (sLBDDS). Design and development of sLBDDS in a pharmaceutical industry setting was the main purpose of this thesis. Methods: The model drugs (celecoxib, cinnarizine, JNJ-2A) and a set of LBDDS based on excipients with different properties were investigated in solubility studies, in vitro dispersion tests and in vitro static or dynamic dispersion/digestion-permeation studies. In vivo behaviour of drugs after administration as LBDDS and/or sLBDDS was evaluated using developed plasma drug quantification methods Results: Firstly, the supersaturation propensity in eight LBDDS was shown to be different for the model drugs. High apparent supersaturation degrees (aDS) were obtained for celecoxib and cinnarizine, while low aDS were found for JNJ-2A Secondly, systematic investigation of lipid excipient influence on in vivo performance of LBDDS showed that simple one or two-component LBDDS have a positive effect on drug absorption relative to three-component systems containing triglycerides. Additionally, a statistically significantly higher drug absorption in case of celecoxib and cinnarizine was seen for some long chain (LC) compared to medium chain (MC) LBDDS. Furthermore, it was indicated that a simplified test using assembled pre- and post-digestive biorelevant media consisting of dispersed or digested lipid excipients can help screen drug solubilization and further inform choice of LC or MC lipid excipients in candidate formulations, while dispersion and dilution testing correlated well with in vivo findings. Thirdly, thermally-induced drug supersaturation in one-component LBDDS resulted in higher celecoxib bioavailability relative to LBDDS, yet the drug supersaturation effect did not result in higher drug permeation in in vitro dispersion/digestion-permeation studies under static or dynamic conditions. Nevertheless, the positive effect of LC LBDDS seen in vivo was also identified in the developed in vitro models. Finally, a negative effect of thermally-induced supersaturation was observed for the precipitation-prone drug, cinnarizine. Nevertheless, cinnarizine absorption was improved by inclusion of precipitation inhibitors (PI) in the formulation, albeit only statistically significant for one sLBDDS-PI. Conclusions: Thermally-induced supersaturation resulted in increased celecoxib bioavailability from sLBDDS relative to LBDDS consisting of mono- and di-glycerides as single lipid excipient. Compositional effects were seen both in in vivo studies and in vitro dispersion/digestion-permeation testing for celecoxib. For cinnarizine, an inherent precipitation risk from sLBDDS was observed independent of lipid system composition. In contrast to celecoxib, thermally-induced supersaturation resulted in lower drug absorption relative to LBDDS, yet a positive influence was observed after inclusion of PIs in the formulations. For JNJ-2A, modest aDS were obtained using the tested lipid systems and only a minor influence of lipid composition was observed in vivo. This thesis showed that sLBDDS can be used for poorly-water soluble drugs as means to increase drug loadings and could be potentially used in preclinical studies to maximise in vivo exposure. Formulation development guidance tools are provided at the end of this thesis to aid scientists in designing and developing sLBDDS.en
dc.description.statusNot peer revieweden
dc.description.versionAccepted Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationIlie, A-R. 2020. Design and development of supersaturated lipid-based drug delivery systems for applications in pharmaceutical industry. PhD Thesis, University College Cork.en
dc.identifier.endpage254en
dc.identifier.urihttps://hdl.handle.net/10468/12024
dc.language.isoenen
dc.publisherUniversity College Corken
dc.relation.projectinfo:eu-repo/grantAgreement/EC/H2020::MSCA-ITN-ETN/674909/EU/Pharmaceutical Education And Research with Regulatory Links: Innovative drug development strategies and regulatory tools tailored to facilitate earlier access to medicines/PEARRLen
dc.rights© 2020, Alexandra-Roxana Ilie.en
dc.rights.urihttps://creativecommons.org/publicdomain/zero/1.0/en
dc.subjectLipid-based drug delivery systemsen
dc.subjectSupersaturated lipid-based drug delivery systemsen
dc.subjectIn vivo-in vitro correlationsen
dc.subjectBiopharmaceutical toolsen
dc.subjectPrecipitation inhibitorsen
dc.subjectDigestion-permeation modelsen
dc.titleDesign and development of supersaturated lipid-based drug delivery systems for applications in pharmaceutical industryen
dc.typeDoctoral thesisen
dc.type.qualificationlevelDoctoralen
dc.type.qualificationnamePhD - Doctor of Philosophyen
Files
Original bundle
Now showing 1 - 3 of 3
Loading...
Thumbnail Image
Name:
IlieAR_PhD2020.docx
Size:
8.95 MB
Format:
Microsoft Word XML
Description:
Full Text E-thesis (Word)
Loading...
Thumbnail Image
Name:
IlieAR_PhD2020.pdf
Size:
4.51 MB
Format:
Adobe Portable Document Format
Description:
Full Text E-thesis
Loading...
Thumbnail Image
Name:
3. 117223111-Alexandra Roxana Llie Submission Form.pdf
Size:
1.76 MB
Format:
Adobe Portable Document Format
Description:
Submission for Examination Form
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
5.2 KB
Format:
Item-specific license agreed upon to submission
Description: